Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
Sylvie Chevret(Saint Louis University Hospital), Sabrina Brahmi, Mehdi Marzouk(Centre Hospitalier de Béthune), E De Montmollin, Guillaume Franchineau(Université Claude Bernard Lyon 1), Imane Zemihi, Juliette Patrier, Moustafa Abdel-Nabey(Assistance Publique – Hôpitaux de Paris), Claire Dupuis(Inserm), Naima Beldjoudi(Assistance Publique – Hôpitaux de Paris), Alice Oubahim, Laura Kramer, Pierre Jaquet(Centre Hospitalier Saint-Denis), Veronique Deiler, Ines Chibane, Paul-Henri Wicky(Associated Research (United States)), Fabrice Sinnah, Alexandra Grinea, Sarra Dalibey, Sabrine Lamri, Jean‐François Timsit(Université Claude Bernard Lyon 1), Faiza Sayagh, Fariza Lamara, Céline Alloux, Kamyl Baghli, Lucie Lefèvre, Fadila Amerali, Aline Fallet, Ghenima Belkessa, Hélène Brocvielle, Béatrice Andriss, Rawan Belmokhtar, Nathalie Barget, Sylia Zmihi, Billal Azzouguen, Yohan Maurer, Nadia Ettalhaoui(Inserm), Lila Bouadma(Université Paris Cité), Marie-Capucine Tellier, Lila Bouadma(Inserm), Romain Sonneville, Yves Cohen, Florence Capelle, Simona Presente, Claire Dupuis(Inserm), Jean-Marc Mintsa, Tiphaine Girard, Charles Burdet(Université Paris Cité)
Cited by 3
Related Papers
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
|Intensive Care Medicine|2020|1.1k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894